View Older Stories View More Recent Stories

Aug 6, 2020 04:01PM Personalis Reports Second Quarter 2020 Financial Results
Aug 5, 2020 04:05PM Sarepta Therapeutics Announces Second Quarter 2020 Financial Results and Recent Corporate Developments
Jul 31, 2020 06:15PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jul 29, 2020 08:30AM Sarepta Therapeutics to Announce Second Quarter 2020 Financial Results and Recent Corporate Developments on August 5, 2020
Jul 24, 2020 08:30AM Sarepta Therapeutics (SRPT) Receives Fast Track Designation for SRP-9001 Micro-Dystrophin Gene Therapy for the Treatment of DMD
Jul 24, 2020 08:30AM Sarepta Therapeutics Receives Fast Track Designation for SRP-9001 Micro-Dystrophin Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
Jul 15, 2020 08:30AM Sarepta Therapeutics Launches “Rare Lessons” Program to Promote Greater Diversity and Inclusion in the Classroom and Support Awareness of Rare Diseases
Jul 2, 2020 07:01AM Sarepta Therapeutics (SRPT) Signs Agreement with Hansa Biopharma for Imlifidase
Jul 2, 2020 07:00AM Sarepta Therapeutics Signs Agreement with Hansa Biopharma for Imlifidase
Jun 30, 2020 06:15PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Jun 30, 2020 08:33AM Sarepta Therapeutics (SRPT) Announces Retirement of Sandy Mahatme, CFO and Chief Business Officer
Jun 30, 2020 08:30AM Sarepta Therapeutics Announces Retirement of Sandy Mahatme, Chief Financial Officer and Chief Business Officer
Jun 26, 2020 08:31AM Sarepta Therapeutics (SRPT) Completes Submission of NDA Seeking Approval of Casimersen for Patients with DMD Amenable to Skipping Exon 45
Jun 26, 2020 08:30AM Sarepta Therapeutics Completes Submission of New Drug Application Seeking Approval of Casimersen (SRP-4045) for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 45
Jun 22, 2020 08:07AM Sarepta Therapeutics (SRPT), Codiak BioSciences Collaborate to Research and Develop Exosome-Based Therapeutics for Rare Diseases
Jun 22, 2020 08:00AM Sarepta Therapeutics and Codiak BioSciences Collaborate to Research and Develop Exosome-Based Therapeutics for Rare Diseases
Jun 18, 2020 08:32AM Sarepta Therapeutics (SRPT), Selecta Biosciences (SELB) Announce Research License & Option Agreement for ImmTOR Immune Tolerance Platform in Neuromuscular Diseases
Jun 18, 2020 08:30AM Sarepta Therapeutics and Selecta Biosciences Enter Into Research License and Option Agreement for Selecta’s ImmTOR Immune Tolerance Platform in Neuromuscular Diseases
Jun 18, 2020 08:30AM Sarepta Therapeutics and Selecta Biosciences Enter into Research License and Option Agreement for Selecta’s ImmTOR Immune Tolerance Platform in Neuromuscular Diseases
Jun 15, 2020 11:01AM Sarepta Therapeutics (SRPT) Announces Positive Safety and Efficacy Data from SRP-9001 Micro-Dystrophin Gene Therapy Trial Published in JAMA Neurology
Jun 15, 2020 11:00AM Sarepta Therapeutics Announces Positive Safety and Efficacy Data from the SRP-9001 Micro-Dystrophin Gene Therapy Trial Published in JAMA Neurology
Jun 8, 2020 08:55AM Sarepta Therapeutics (SRPT) Announces Positive Expression and Functional Data From SRP-9003 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E
Jun 8, 2020 08:55AM Sarepta Therapeutics Announces Positive Expression and Functional Data From the SRP-9003 Gene Therapy Trial to Treat Limb-Girdle Muscular Dystrophy Type 2E
Jun 5, 2020 04:06PM Sarepta Therapeutics (SRPT) to Share Clinical Update from SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
Jun 5, 2020 04:05PM Sarepta Therapeutics to Share Clinical Update from SRP-9003 Gene Therapy Trial to Treat Limb-girdle Muscular Dystrophy Type 2E, or Beta-Sarcoglycanopathy
Jun 2, 2020 05:00PM Sarepta Therapeutics to Present at Upcoming Investor Conferences
Jun 2, 2020 08:00AM Personalis Announces Scientific Collaboration with Sarepta Therapeutics on Immune Response to Precision Genetic Therapeutics
May 29, 2020 06:27PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 12, 2020 04:30PM Sarepta Therapeutics to Present at the 2020 RBC Capital Markets Virtual Global Healthcare Conference
May 11, 2020 07:00AM Sarepta Therapeutics and Dyno Therapeutics Announce Agreement to Develop Next-Generation Gene Therapy Vectors for Muscle Diseases
May 6, 2020 04:05PM Sarepta Therapeutics Announces First Quarter 2020 Financial Results and Recent Corporate Developments
Apr 30, 2020 06:52PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Apr 29, 2020 08:30AM Sarepta Therapeutics to Announce First Quarter 2020 Financial Results and Recent Corporate Developments on May 6, 2020
Apr 28, 2020 08:34AM Sarepta Therapeutics (SRPT) Reports Research Agreement with U.S. DoD to Evaluate Proprietary RNA Platform for COVID-19 Treatments
Apr 28, 2020 08:30AM Sarepta Therapeutics Announces Research Agreement with U.S. Department of Defense to Evaluate Multiple Constructs From its Proprietary RNA Platform as Treatments for COVID-19
Mar 31, 2020 06:06PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 28, 2020 06:20PM Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 27, 2020 08:30AM Sarepta Therapeutics Announces Third Year of Route 79, The Duchenne Scholarship Program
Feb 26, 2020 04:05PM Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2019 Financial Results and Recent Corporate Developments
Jan 16, 2020 11:10AM UPDATE: Axalta (AXTA) Viewed as Most Likely Takeover Target in Survey of M&A Desks - Bloomberg
Jun 28, 2019 10:16AM Pfizer (PFE) Presents Initial Clinical Data on Phase 1b Gene Therapy Study for DMD
Feb 7, 2019 09:27AM Pre-Open Stock Movers 02/07: (IRBT) (LCI) (STI) Higher; (SLDB) (OSUR) (GRUB) Lower (more...)
Sep 7, 2018 08:50AM Parent Project Muscular Dystrophy and Sarepta Therapeutics Partner to Launch Duchenne Outcomes Research Interchange, a Patient-Data Warehouse Serving the Entire Duchenne Community
Jul 23, 2018 02:24PM Sarepta Therapeutics, Inc. and CureDuchenne to Host Webinar on Duchenne Muscular Dystrophy Programs Utilizing Sarepta’s RNA-Targeted Technology Platforms
Jan 17, 2018 09:10AM First Duchenne Muscular Dystrophy Patient Dosed in Systemic Microdystrophin Gene Therapy
Oct 26, 2017 09:27AM Pre-Open Movers 10/26: (MNOV) (BWLD) (TWTR) Higher; (IDRA) (CELG) (NTRI) Lower (more...)
Sep 5, 2017 10:00AM Sarepta Therapeutics, Inc. (Nasdaq: SRPT) to Ring The Nasdaq Stock Market Closing Bell
Oct 26, 2016 02:46PM Trading Radar for 10/27: Alphabet (GOOG), Amazon (AMZN), Twitter (TWTR) Ford (F), Baidu.com (BIDU) Report
Oct 6, 2016 12:08PM CureDuchenne to Host SareptAssist Webinar on October 11 to Provide an Overview of Sarepta’s Patient Support Program for Duchenne Families
Oct 4, 2016 09:22AM Pre-Open Stock Movers 10/04: (SMMT) (SDRL) (ARLZ) Higher; (TRIB) (IRMD) (TWTR) Lower (more...)
View More Recent Stories View Older Stories